Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J asks MHRA for antifungal switch

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson's McNeil division requests the U.K. Medicines and Healthcare products Regulatory Agency switch its antifungal Daktarin Intensiv Cream (ketoconazole 2%) from pharmacy to general sale list status. The same active ingredient is found in J&J's Nizoral Anti-dandruff Shampoo which has been GSL in the U.K. since 2001 and switched to U.S. OTC sale in 1997 (1"The Tan Sheet" Jan. 28, 2002)

You may also be interested in...



Johnson & Johnson President Brings Extensive McNeil Background To Post

Johnson & Johnson's appointment of James Lenehan, 53, as president signals a strong commitment by the company to its consumer products segments, despite the firm's shift in emphasis toward its pharmaceutical business over the past ten years

Digitizing Molecules To Create Novel Antibiotics

An early childhood fascination with the natural world led Cesar de la Fuente into the fields of microbiology and immunology. A PhD from the University of British Columbia – and postdoc work at Massachusetts Institute of Technology – helped him combine computer science principles with biological processes. As the leader of a machine biology group and lab at the University of Pennsylvania, de la Fuente is working to develop new antibiotics to treat deadly bacterial infections.

Trust Us: Is Pharma’s COVID-19 Vaccine Pledge Convincing?

Missteps on convalescent plasma and the revoked authorization of hydroxychloroquine – paired with US president Trump’s cheerleading for the rapid approval of a COVID-19 vaccine – has eroded public trust in the US FDA. Can a safety and efficacy pledge from vaccine developers tamp down public skepticism?

Topics

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel